Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Biomarin Pharmaceutical Inc. has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 5 distinct examiners and 5 distinct art units. This distribution indicates that each pending matter is being reviewed by a different examiner in a different specialized division of the patent office.
The busiest examiner, HELLMAN, KRISTINA M, is responsible for 1 pending office action. With 5 distinct examiners and 5 distinct art units involved, the portfolio's current prosecution is distributed across multiple points of review. This structure shows that the company's pharmaceutical and biotechnological innovations fall under various technical classifications. The 5 pending office actions are handled by 5 distinct examiners, ensuring that each matter in the Biotechnology & Pharmaceuticals area is evaluated within its own distinct art unit. HELLMAN, KRISTINA M manages 1 pending office action as part of this distribution.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (40%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HELLMAN, KRISTINA M | 1 | 65.3% | +55.3% |
| ALLEN, MICHAEL D | 1 | 32.0% | +49.4% |
| TRAN, CHRISTINA L | 1 | 51.6% | +48.2% |
| KOROTCHKINA, LIOUBOV G | 1 | 29.5% | +67.7% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17634034 | Hydrophobic Peptide Salts for Extended Release Compositions | REYNOLDS, FRED H | 334d overdue |
| 18273430 | AAV PRODUCTION SYSTEMS FOR AAV VIRAL PARTICLES WITH IMPROVED INFECTIVITY | ALLEN, MICHAEL D | 22d overdue |
| 18785340 | Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia | HELLMAN, KRISTINA M | — |
| 17638029 | Methods for Treating CLN2 Disease in Pediatric Subjects | KOROTCHKINA, LIOUBOV G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17634034 | Hydrophobic Peptide Salts for Extended Release Compositions | REYNOLDS, FRED H | 334d overdue |
| 18273430 | AAV PRODUCTION SYSTEMS FOR AAV VIRAL PARTICLES WITH IMPROVED INFECTIVITY | ALLEN, MICHAEL D | 22d overdue |
| 18785340 | Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia | HELLMAN, KRISTINA M | — |
| 18192480 | DYSTROPHIN EXON SKIPPING OLIGONUCLEOTIDES | TRAN, CHRISTINA L | — |
| 17638029 | Methods for Treating CLN2 Disease in Pediatric Subjects | KOROTCHKINA, LIOUBOV G | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1671 | 1 |
| 1637 | 1 |
| 1653 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18785340 | Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia | HELLMAN, KRISTINA M | 1654 | §101§102§103§112Other | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18273430 | AAV PRODUCTION SYSTEMS FOR AAV VIRAL PARTICLES WITH IMPROVED INFECTIVITY | ALLEN, MICHAEL D | 1671 | §102§103§112 | Non-Final OA | 22d overdue | Pending | Jul 20, 2023 |
| 18192480 | DYSTROPHIN EXON SKIPPING OLIGONUCLEOTIDES | TRAN, CHRISTINA L | 1637 | §103DP | Final Rejection | — | Pending | Mar 29, 2023 |
| 17638029 | Methods for Treating CLN2 Disease in Pediatric Subjects | KOROTCHKINA, LIOUBOV G | 1653 | §103§112DP | Non-Final OA | — | Pending | Feb 24, 2022 |
| 17634034 | Hydrophobic Peptide Salts for Extended Release Compositions | REYNOLDS, FRED H | 1658 | §101§102§103§112Other | Non-Final OA | 334d overdue | Pending | Feb 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial